about
Immunization of mice with YscF provides protection from Yersinia pestis infectionsPlant-produced candidate countermeasures against emerging and reemerging infections and bioterror agentsPlague Vaccine Development: Current Research and Future TrendsEmerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious DiseasesHuman anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague modelThe twin arginine translocation system is essential for virulence of Yersinia pseudotuberculosis.Evaluation of combinatorial vaccines against anthrax and plague in a murine modelEffect of MarA-like proteins on antibiotic resistance and virulence in Yersinia pestisImmune defense against pneumonic plagueDirect neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrVPurification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infectionHost Iron Nutritional Immunity Induced by a Live Yersinia pestis Vaccine Strain Is Associated with Immediate Protection against Plague.Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.LcrV plague vaccine with altered immunomodulatory propertiesAnti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis.Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaquesLcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.Administration of antibody to the lung protects mice against pneumonic plague.The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection.A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plagueHumoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.Protection against pneumonic plague following oral immunization with a non-replicating vaccine.Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.Yersinia pestis caf1 variants and the limits of plague vaccine protection.Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.Current challenges in the development of vaccines for pneumonic plague.Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestisStructure and assembly of Yersinia pestis F1 antigen.Technical transformation of biodefense vaccines.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
P2860
Q24815169-63CA7600-8EB2-4B0D-A008-DA56F29CFC63Q26783107-E1F61AE3-CF14-4299-9DCD-2CBDCE1A2A16Q28066875-09CEB1CF-BE10-4545-A3FA-8B6D7181D139Q28383084-A819BB29-F758-4DFA-8E79-1D0E74C7D055Q28748886-E9D38AE8-FB05-4EA8-9EB6-C1C3DB5E295FQ28768225-51B0302C-7052-405F-AD15-E027C2F74F98Q33283821-34AA8C5A-E90A-425E-B14E-7A30E633D886Q33557913-4795DC3C-431C-44C8-A1C3-2A1070C6B58EQ33584403-4BFE8481-51D8-4F5B-BFF6-403D3BF2F864Q33601814-BC8D9F02-E98A-4B6B-A6F7-59F7A09C961BQ33612949-3A1C7522-CBD9-442C-A921-46893DD383FBQ33635050-B24A6DC0-0EC3-47FB-8F29-1E902B26DC68Q33675781-BE60271B-C18F-4850-8EE5-92A840BEC825Q33675834-80ACD0BD-B76C-4FEF-B25D-E5588E652189Q33819353-09FCA279-75D1-4C74-9A87-4171161677F2Q33824782-CC5268F3-7BBD-4E91-9026-2FFA19C70855Q33946882-B93A575F-144E-4885-9C83-B0FCD09A4DAFQ34034184-199F489E-8E0A-4ED6-A609-7E07E0D07EC1Q34123275-437C3610-D990-4168-B9EE-F7CD1157F565Q34290878-61B5969D-F13D-4499-B7C9-CD5974A75FEBQ34298699-A710D633-D828-4C72-A11F-E4E3C85ABB30Q34394184-8A0ECDC7-4D54-49F5-95D7-E93391854FEFQ34601788-C1896884-B270-4EAB-A785-A013CF173ABFQ34681213-54C34273-EE8F-4B5F-83B1-EBD53BB7CA61Q34778198-10239A03-3DAC-49BA-8C80-A3A9C941CAC7Q34786724-F116939D-C4DE-4786-99C2-0F7C2FA5188FQ35530270-CEAFAEA4-EBC5-470E-8950-27431E2DDF5EQ35739128-137B054A-DEC3-4FCE-A750-034850855B8AQ35826610-70770FCA-4E66-4E1F-AF57-4B01134F1EC3Q35998760-B4AC8114-FFF6-4C4E-93E7-5FB0F1DB5500Q36099515-D8656AC7-1AB5-446A-8A87-39925EA061E3Q36539626-C0626EF7-0E10-4F4D-8D2C-6F1FE758F4C7Q36594087-E9831949-2A58-4A48-BB4A-8528E8655180Q36606805-1DE47F6D-30D8-41DE-BB4C-F3A3B13A9399Q36628038-0AA8CA11-DCF5-412A-B1DE-DB4D0A72747FQ36911486-415A08A8-89C1-4EE9-84E0-92FD6C6B4633Q36950063-89386B06-01A4-4F7D-9B5C-01C9226D3C41Q36983994-D31C1E50-E943-484E-A740-F7647194A541Q37058898-BB05A02C-B9E1-4E98-A5BE-7A746CE1E920Q37066697-A8125D25-4BAB-459B-AC25-A1BA56DB3B5C
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Yersinia pestis (plague) vaccines.
@ast
Yersinia pestis (plague) vaccines.
@en
Yersinia pestis
@nl
type
label
Yersinia pestis (plague) vaccines.
@ast
Yersinia pestis (plague) vaccines.
@en
Yersinia pestis
@nl
prefLabel
Yersinia pestis (plague) vaccines.
@ast
Yersinia pestis (plague) vaccines.
@en
Yersinia pestis
@nl
P2860
P356
P1476
Yersinia pestis (plague) vaccines.
@en
P2093
E Diane Williamson
P2860
P304
P356
10.1517/14712598.4.6.965
P407
P577
2004-06-01T00:00:00Z